RT Journal Article
SR Electronic
T1 Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.17.20061440
DO 10.1101/2020.04.17.20061440
A1 Braun, Julian
A1 Loyal, Lucie
A1 Frentsch, Marco
A1 Wendisch, Daniel
A1 Georg, Philipp
A1 Kurth, Florian
A1 Hippenstiel, Stefan
A1 Dingeldey, Manuela
A1 Kruse, Beate
A1 Fauchere, Florent
A1 Baysal, Emre
A1 Mangold, Maike
A1 Henze, Larissa
A1 Lauster, Roland
A1 Mall, Marcus A.
A1 Beyer, Kirsten
A1 Röhmel, Jobst
A1 Schmitz, Jürgen
A1 Miltenyi, Stefan
A1 Demuth, Ilja
A1 Müller, Marcel A.
A1 Witzenrath, Martin
A1 Suttorp, Norbert
A1 Kern, Florian
A1 Reimer, Ulf
A1 Wenschuh, Holger
A1 Drosten, Christian
A1 Corman, Victor M.
A1 Giesecke-Thiel, Claudia
A1 Sander, Leif Erik
A1 Thiel, Andreas
YR 2020
UL http://medrxiv.org/content/early/2020/04/22/2020.04.17.20061440.abstract
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a rapidly unfolding pandemic, overwhelming health care systems worldwide1. Clinical manifestations of Coronavirus-disease 2019 (COVID-19) vary broadly, ranging from asymptomatic infection to acute respiratory failure and death2, yet the underlying mechanisms for this high variability are still unknown. Similarly, the role of host immune responses in viral clearance of COVID-19 remains unresolved. For SARS-CoV (2002/03), however, it has been reported that CD4+ T cell responses correlated with positive outcomes3,4, whereas T cell immune responses to SARS-CoV-2 have not yet been characterized. Here, we describe an assay that allows direct detection and characterization of SARS-CoV-2 spike glycoprotein (S)-reactive CD4+ T cells in peripheral blood. We demonstrate the presence of S-reactive CD4+ T cells in 83% of COVID-19 patients, as well as in 34% of SARS-CoV-2 seronegative healthy donors (HD), albeit at lower frequencies. Strikingly, S-reactive CD4+ T cells in COVID-19 patients equally targeted N-terminal and C-terminal epitopes of S whereas in HD S-reactive CD4+ T cells reacted almost exclusively to the C-terminal epitopes that are a) characterized by higher homology with spike glycoprotein of human endemic “common cold” coronaviruses (hCoVs), and b) contains the S2 subunit of S with the cytoplasmic peptide (CP), the fusion peptide (FP), and the transmembrane domain (TM) but not the receptor-binding domain (RBD). In contrast to S-reactive CD4+ T cells in HD, S-reactive CD4+ T cells from COVID-19 patients co-expressed CD38 and HLA-DR, indivative of their recent in vivo activation. Our study is the first to directly measure SARS-CoV-2-reactive T cell responses providing critical tools for large scale testing and characterization of potential cross-reactive cellular immunity to SARS-CoV-2. The presence of pre-existing SARS-CoV-2-reactive T cells in a subset of SARS-CoV-2 naïve HD is of high interest but larger scale prospective cohort studies are needed to assess whether their presence is a correlate of protection or pathology for COVID-19. Results of such studies will be key for a mechanistic understanding of the SARS-CoV-2 pandemic, adaptation of containment methods and to support vaccine development.Competing Interest StatementThe authors Jürgen Schmitz, Stefan Miltenyi, Florian Kern, Ulf Reimer, Holger Wenschuh are employed at non-academic cooperations.Funding StatementWe thank Ulf Klein (Leeds, UK) und Hans-Peter Herzel (Berlin) for critical discussion. This work was supported by the German Research Foundation (KFO339 to J.B and F.F., SFB-TR84 projects A4, B6 to S.H., B8 to M.M., C6 to M.W., C8, C10 to L.E.S., C9 to M.W, N.S., and by the German Federal Ministry of Education and Research (BMBF-RAPID to S.H., C.D., and CAPSyS to M.W., N.S.).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred two the manuscript ist available.